Clinical trial
Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit - Repeat ExpoSure to AntimicRobial Therapy (RESTART)
NCT05171257 is registered in ClinicalTrials.gov with Methodist Health System as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit - Repeat ExpoSure to AntimicRobial Therapy (RESTART)
- Lead sponsor
- Methodist Health System
- Phase
- Observational
- Overall status
- Completed
- Start date
- October 19, 2021
- Completion date
- July 14, 2025
- Enrollment
- 197 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.